FDA Approval of generic mifepristone and relate Risk Evaluation Mitigation Strategies (REMS)
2025 · 3rd Quarter (July 1 - Sep 30)
GENBIOPRO, INC.
Filed by EMERGENT STRATEGIES.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $35,000.00
- Expenses
- Not reported
- Registrant
- EMERGENT STRATEGIES
- Client
- GENBIOPRO, INC.
- Filing UUID
- 1a7765fb-a7d2-44da-b53d-3ab9c358a2d6
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
VA rule making on providing abortion services to veterans
Issues related to medication abortion; Issues related to abortion access
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.